Advanced Virus Detection Technologies Interest Group (AVDTIG): Efforts on High Throughput Sequencing (HTS) for Virus Detection

Reference

1. 1.↵
   1. Khan A. S.,
   2. King K.E.,
   3. Brack K.,
   4. Cassart J-P.,
   5. Chiu C.,
   6. Dehghani H.,
   7. Duncan P.,
   8. Jaing C.,
   9. Kolman J.,
   10. Munroe D.,
   11. Palermo A.,
   12. Plavsic M.,
   13. Sampath R.,
   14. Slezak T.,
   15. Takle G.,
   16. Taliaferro L.P.,
   17. Toso E.,
   18. Vacante D.,
   19. Willkommen H.,
   20. et al

   . Emerging Methods for Virus Detection, Technical Report No. 71. Parenteral Drug Association, 2015.
2. 2.↵
   Quality Guideline Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin; International Conference on Harmonisation: 1999, www.ich.org (accessed April 23, 2016).
3. 3.↵
   Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; U.S. Food and Drug Administration, 2010, http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf (accessed April 23, 2016).
4. 4.↵
   Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks: TRS 878, Annex 1. World Health Organization, 2010, http://www.who.int/biologicals/Cell_Substrates_clean_version_18_April.pdf (accessed April 23, 2016).
5. 5.↵
   Quality Guideline Q5D: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products; International Conference on Harmonisation, 1998, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003280.pdf (accessed April 23, 2016).
6. 6.↵
   1. Khan A. S.

   Testing Considerations for Novel Cell Substrates: A Regulatory Perspective. PDA J. Pharm. Sci. Technol. 2010, 64 (5), 426–431.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Victoria J.,
   2. Wang C.,
   3. Jones M. S.,
   4. Jaing C.,
   5. McLoughlin K.,
   6. Gardner S.,
   7. Delwart E. L.

   Viral Nucleic Acids in Live-Attenuated Vaccines: Detection of Minority Variants and an Adventitious Virus. J. Virol. 2010, 84 (12), 6033–6040.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2012 Meeting Materials: Vaccines and Related Biological Products Advisory Committee; U.S. Food and Drug Administration, 2012, http://www.fda.gov/advisorycommittees/committeesmeetingma-terials/bloodvaccinesandotherbiologics/vaccine-sandrelatedbiologicalproductsadvisorycommittee/ucm288695.htm, (accessed April 23, 2016).
9. 9.↵
   1. Sheets R.,
   2. Loewer J.,
   3. Raychaudhuri G.,
   4. Petricciani J.

   Adventitious Agents, New Technology, and Risk Assessment, 19-20 May 2011, Baltimore, MD. Biologicals 2012, 40 (2), 162–167.

   OpenUrlPubMed
10. 10.↵
    1. Khan A.,
    2. Lubiniecki A.,
    3. King K. E.

    PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, November 2–4, 2011, Rockville, MD. PDA J. Pharm. Sci. Technol. 2012, 66 (6), 502–511.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Khan A.,
    2. Vacante D. A.

    Introduction and Workshop Summary: PDA/FDA Advanced Technologies for Virus Detection in the Evaluation of Biologicals: Applications and Challenges. PDA J. Pharm. Sci. Technol. 2014, 68 (6), 546–547.

    OpenUrlFREE Full Text